Observance et persistance: impact sur l'efficience des traitements de l'osteoporose

[en] Low adherence to therapies has been repeatedly described as a major determinant of poor clinical outcomes in chronic disorders. Bisphosphonates, the most widely prescribed drugs in this field, have been linked to a 12-month persistence lower than 40%. The situation is improved when using the weekly formulation compared to the daily intake of the drug. Low compliance results in lesser increase in bone mineral density and decreased anti-fracture efficacy. New medications, currently developed for the management of osteoporosis, will be user-friendly, allowing to an improvement of compliance and persistence.
[fr] Une faible adhérence a été systématiquement reliée à une moins bonne efficacité thérapeutique, lors de la prise en charge des maladies chroniques. Les bisphosphonates, médicaments les plus largement prescrits pour le traitement de l’ostéoporose, sont grevés d’une persistance à douze mois inférieure à 40%. La situation a été améliorée, de manière insuffisante, par le passage d’une prise quotidienne à une prise hebdomadaire. Une faible observance ou persistance, s’accompagne d’un gain de masse osseuse réduit et d’une moindre efficacité anti-fracturaire. Les nouveaux médicaments actuellement développés dans l’ostéoporose privilégieront le caractère convivial, permettant d’optimaliser l’adhérence au traitement.

Disciplines :

Rheumatology

Author, co-author :

Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique

Rabenda, Véronique ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique

Language :

French

Title :

Observance et persistance: impact sur l'efficience des traitements de l'osteoporose

Alternative titles :

[en] Adherence to Treatment in Osteoporosis Influence on Efficiency

Publication date :

05 October 2005

Journal title :

Revue Médicale Suisse

ISSN :

1660-9379

Publisher :

Medecine et Hygiène, Switzerland

Volume :

Issue :

Pages :

2278-81

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 27 August 2009

Statistics

Number of views

120 (9 by ULiège)

Number of downloads

10 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Sung JC, Nichol MB, Venturini F, et al. Factors affecting patient compliance with antihyperlipidemic medications in an HMO population. Am J Manag Care 1998;4:421-30.
Giuffrida A, Torgerson DJ. Should we pay the patient? Review of financial incentives to enhance patient compliance. BMJ 1997;315:703-7.
Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: A cross-national study. JAMA 1998;279:458-62.
Reginster JY, Lecart MP. Treatment of osteoporosis with bisphosphonates - Do compliance and persistence matter? Business Briefing: Long-term Healthcare, 2004;65-8.
Sullivan S, Kreling D, Hazlet TH. Non-compliance with medication regimens and subsequent hospitalizations: A literature analysis and cost of hospitalization estimate. J Res Pharmac Econom 1990;2:19-33.
Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 1997;102:43-9.
Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003;115:209-16.
Lombas C, Hakim C, Zanchetta JR. Compliance with alendronate treatment in an osteoporosis clinic. J Bone Miner Res 2001;15(Abstract M406):S529.
Bard R, Goette S, Hadji P, et al. Persistence and compliance with daily and weekly-administered bisphosphonates for osteoporosis treatment in Germany. Osteoporos Int 2005;4:S45.
Cramer JA, Amonkar MM, Hebborn A, et al. Does dosing regimen impact persistence with bisphosphonates therapy among postmenopausal osteoporotic women? J Bone Miner Res 2004;19:S448.
Recker RR, Gallagher R, Amonkar M, et al. Medication persistence is better with weekly bisphosphonates, but it remains suboptimal. J Bone Miner Res 2004;19:S172.
Sebaldt RJ, Shane LG, Pham BZ, et al. Longer-term effectiveness outcomes of non-compliance and non-persistence with daily-regimen bisphosphonates therapy in patients with osteoporosis treated in tertiary specialist care. Osteoporos Int 2004;15:S107.
Eastell R, Garnero P, Vrijens L, et al. Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: The impact study. Calcif Tissue Int 2003;72 (Abstract P-297).
McCombs JS, Thiebaud P, McLaughlin-Miley C, et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48:271-87.
Caro JJ, Ishak KJ, Huybrechts KF, et al. Clinical and economic impact of adherence to osteoporosis medication. Osteoporos Int 2003;14:S2.